Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-T) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7  + 3 Cytarabine and Daunorubicin

CPX-351 is a dual-drug liposomal encapsulation of cytarabine (C) and daunorubicin (D) that delivers a synergistic 5:1 drug ratio and is FDA-approved for adults with newly diagnosed therapy-related AML or AML with MDS-related changes. In a randomized, phase 3 study (NCT01696084) in patients (pts) 60-75 y with newly diagnosed sAML, CPX-351 significantly improved overall survival (OS) and remission rates vs 7  + 3. RAEB-t AML, often defined as bone marrow blasts 20%-29%, shares many features with myelodysplastic syndrome (MDS).

Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Tara L. Lin, Geoffrey L. Uy, Matthew J. Wieduwilt, Laura F. Newell, Robert K. Stuart, Bruno C. Medeiros, Gary J. Schiller, S. Eric Rubenstein, Wendy Stock, Erica Warlick, Matthew Foster, Dale L. Bixby, Nikolai Podoltsev, Qi An, Stefan Faderl, Arthur C. Lo Source Type: research